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Topical zoledronic acid decreases
micromotion induced bone resorption in a
sheep arthroplasty model
Thomas Jakobsen1,2*, Søren Kold1,2, Juan Shiguetomi-Medina1, Jorgen Baas1, Kjeld Soballe1 and Ole Rahbek1
Abstract
Background: Initial micromotion of a total hip replacement is associated with aseptic loosening. The use
of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Bisphosphonates compounds are inhibitors of bone resorption. The aim of this study was to investigate whether
local treatment with bisphosphonate would reduce bone resorption and fibrous tissue around an experimental
implant subjected to micromotion.
Methods: One micromotion implant were inserted into each medial femoral condyle in ten sheep. During each
gait cycle the implant axially piston 0.5 mm. During surgery one of the femoral condyles were locally treated with
0.8 mg zoledronate. The other condyle served as control. Observation period was 12 weeks.
Results: Histological evaluation showed a fibrous capsule around both the control and bisphosphonate implants.
Histomorphometrical analysis showed that 97% of the surface on both control and bisphosphonate implants were
covered by fibrous tissue. However, the bisphosphonate was able to preserve bone in a 1 mm zone around the
implants.
Conclusion: This study indicates that local treatment with bisphosphonate cannot prevent the formation of a
fibrous capsule around an implant subjected to micromotion, but bisphosphonate is able to reduce resorption of
peri-prosthetic bone.
Keywords: Bisphosphonate, Osseointegration, Implant, Animal, Arthroplasty
Background
Initial stable implant fixation is important for long-term
survival of total joint replacements [1, 2]. Radiostereo-
metrical studies indicate that early migration is a
associated with later revision [1–3]. Treatment strategies
that optimize initial implant fixation and prevents early
implant migration could have the potential to reduce
risks of later revision.
Failure of initial implant osseointegration will result in
early implant migration and bone resorption [4]. Early
implant migration is associated with reduced resistance
to withstand implant movement induced by external
load [5]. Continues implant migration is associated with
implant failure [3]. Early bone resorption can be initiated
by an unstable implant generating micro-movement or
fluid pressure [6–8]. We have previously shown that
implant micromotion without the presence of wear
debris can generate a fibrous membrane and cause bone
resorption [9]. In vivo studies suggest that instability
induced bone resorption works through similar mo-
lecular mechanisms as particle induced bone resorp-
tion [10, 11]. Aseptic loosening of an implant involves
several steps. One of the first steps could be bone
resorption due to micro-movement of the implant.
The resorption bone is replaced with fibrous tissue.
Wear debris will subsequently migrate from the joint
articulation along the fibrous tissue to the bone to implant
interface and aggravate the process [12, 13]. Longevity of
the implant might potentially be increased if micro-* Correspondence: Thomas.Jakobsen@ki.au.dk1Orthopaedic Research Laboratory, Department of Orthopaedics, Aarhus
University Hospital, Norrebrogade 44, Building 1A, DK-8000 Aarhus, Denmark
2Department of Orthopaedics, Aalborg University Hospital, Aalborg, Denmark
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jakobsen et al. BMC Musculoskeletal Disorders  (2017) 18:441 
DOI 10.1186/s12891-017-1802-z
movement of the implant were not allowed to induce
bone resorption.
One way to reduce micromotion induced bone resorp-
tion and fibrous membrane formation could be with the
use of bisphosphonates. These compounds binds strongly
to bone, inhibit osteoclastic activity, and reduce bone
resorption [14]. Systemic bisphosphonate treatment has
previously in an experimental model of osteolysis been
able to reduce bone resorption [15]. We have previously
shown that local treatment with bisphosphonate can in-
crease new bone formation, preserve lamellar bone and
allograft, and increase biomechanical implant fixation in
an experimental joint replacement model [9]. In a clinical
study, local treatment with bisphosphonate was shown to
reduce acetabular component migration measured by
radiostereometrical analysis [16]. The same effect has been
observed in the study investigating local ibandronate treat-
ment in total knee arthroplasties [17]. Others have shown
the local or systemic treatment with bisphosphonates can
reduce but not prevent osteolytic bone resorption and
formation of fibrous tissue in a rat model of prosthetic
loosening [18, 19]. Our group has previously shown in a
large animal model that systemic alendronate can reduce
bone resorption around unstable implants but not prevent
it [20]. A stronger stimulus might be needed. Only way to
obtain a stronger stimulus could be with topical adminis-
tration of a third generation bisphosphonate. The aim of
this study was to investigate in a sheep arthroplasty model
whether topical treatment with bisphosphonate would
reduce bone resorption and fibrous tissue.
We tested the hypothesis that local zoledronate treat-
ment would reduce bone resorption and fibrous tissue
formation around implants subjected to micromotion.
Methods
Study design
We used 10 skeletally mature Danish Landrace sheep
with a mean weight of 40 kg (range, 35–50 kg). The
sheep were obtained though our Institutional farm
(Påskehøjgaardcentret, 8380 Trige, Denmark) affiliated
with our Research facility. Our Institutional Animal Care
and Use Committee approved the study. Institutional
guidelines for the treatment and care of experimental
animals were followed.
In this study, we used a paired design with intervention
and control group in the same sheep. We have previously
shown that the used model of micromotion is able to in-
duce bone resorption [9]. In each sheep, we inserted one
loaded micromotion device (Fig. 1) into each of the medial
femoral condyles. Zoledronate was administered locally in
one of the knees. Saline was used as control in the contra-
lateral knee. The zoledronate and control implants were
systematically alternated between left and right knee. Our
observation period was 12 weeks.
Our sample size calculation was based on a previous
study [9]. We assumed the standard deviation of the
relative change to be 50%. Two-sided α and β were set
to 5% and 20%, respectively. We added two extra ani-
mals to the calculated sample size of eight to counteract
if implants from one or two animals were lost for subse-
quent analysis.
Implants
We used 20 custom-made micromotion implant devices
(Fig. 1). Our micromotion device has previously been
described in detail [9, 21]. In short, the micromotion de-
vice allows a polymethylmethacrylate (PMMA) implant
to piston 0.5 mm with respect to the bone during each
step the animal takes. The micromotion creates shear
forces in the bone to implant interface. The implants in
this study were made sterile by gamma irradiation (25–
50 kGy for 16 h, Codan Steritex, Espergaerde, Denmark).
Surgery
With the sheep under general anesthesia, we used our
standard anteromedial surgical approach to the knee
[9, 21, 22]. Our micromotion device was inserted into
the weight-bearing portion of the medial femoral
condyle. The procedure has been described in detail
in our previously study [9]. During each surgery, we
tested and assured that the micromotion device would
piston during each gait cycle.
Before the PMMA implant was mounted onto the an-
chor screw, we soaked the bone cavity for 60 s with either
saline as control or 1 mL saline containing 0.8 mg zole-
dronate (Aclasta, Novartis Healthcare A/S, Copenhagen,
Denmark) as intervention. After soaking the bone for 60 s,
the cavity was rinsed with saline and excess zoledronate
or saline together with blood coming from the marrow
cavity was sucked away. In this study, all sheep were
weight bearing on the operated leg within 5 days of
surgery. After the 12 weeks observation period the sheep
were euthanized with an overdose of hypersaturated
barbiturate and the bones were collected for preparation
and analyses. At harvest, all pistons were movable.
Specimen preparation
Bone specimens were stored at −20 °C immediately. We
cut each specimen perpendicular to the long axis of the
implant using a water-cooled bad saw (Exact Apparatebau,
Nordenstedt, Germany) (Fig. 2). The specimens was fixed
in 70% ethanol and used for later analysis. Preparation
and subsequent evaluation were blinded.
Histology and Histomorphometry
All bone-implant specimen were dehydrated in ethanol
(70%–96%) containing basic fuchsin, and embedded in
Epoxy (EPOFIX, Struers, Copenhagen, Denmark). Four
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25-μm thick sections were cut with a hard tissue
microtome (KDG-95, MeProTech, Heerhugowaard, The
Netherlands) around the center part of each implant
[23]. The sections were cut with a distance of 400 μm.
Before making the sections, the implant was randomly
rotated around its long axis. The sections were cut
parallel to this axis. These techniques provide reliable
results with negligible bias [24]. Before the sections were
mounted on glass, we surface stained them with 2%
light-green (BDH Laboratory Supplies, Poole, England).
We used a stereological software program (newCAST,
Visiopharm A/S, Horsholm, Denmark) for the histomor-
phometrical analysis. Volume fractions of bone were
estimated by point counting [25] in a zone from the im-
plant surface and 1 mm into the surrounding bone.
Fractions of bone in contact with the implant surface
were estimated using sine-weighted lines [26].
Statistical analysis
Intercooled Stata 9.0 (Stata Inc., College Station, TX,
USA) were used for statistical analysis. Statistical
analyses were done on ratios between paired data, which
were not normally distributed. All variables were log-
transformed and Student’s paired t-test was performed
on absolute differences between normally distributed
log-transformed paired data. An absolute difference
between the logarithms of a pair of data equals the
logarithm of the ratio within the pair [27].
Results
Surgery
One sheep died during surgery and was excluded. The
remaining 9 sheep completed the 12-weeks observation
period. No clinical signs of infection were present at
time of euthanization.
Histology
The most striking difference between the control and
zoledronate implants was the presence of a 200–300 μm
thick fibrous membrane around the control implants
(Fig. 3). A fibrous membrane was also present around
the zoledronate implants, but the membrane was thinner
with an approximately thickness of 50 μm. The fibrous
membrane in both the control and zoledronate group
consisted of dense paralleled fibers. No qualitative mor-
phological difference was found between the two groups
Fig. 2 Schematic diagram showing the specimen preparation. Each bone-implant specimen is embedded and cut into four slides for
histomorphometrical analysis. Reproduced with permission from copyright holder/author
Fig. 1 Schematic drawing showing implant position in the medial femoral condyle. Reproduced with permission from copyright holder/author
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when looking at the bone in the peri-implant zone. The
bone consisted mainly of lamellae with spindle-shaped
osteocytes in between. Sparse amount of osteoclasts
were observed in both groups. No retained bone debris
was observed in any of the groups.
Histomorphometrical analysis
The local zoledronate treatment preserved 14% (p = 0.02)
more total bone around the implants in a 1 mm zone
in the zoledronate group compared to the control
group (Fig. 4). We found a total peri-implant bone
volume fraction of 57% (95% CI: 46% - 67%) in the
control group and 66% (95% CI: 53% - 78%) in the
zoledronate group. No statistically significant changes
were found when comparing bone volume fractions
for woven (p = 0.08) or lamellar (p = 0.32) bone
(Fig. 3). In the zoledronate group, 16% (95% CI: 2% -
29%) of 1 mm peri-implant zone was made of fibrous
tissue compared to 23% (95% CI: 14% - 33%) in the
control group (p = 0.22).
The implant surfaces in the both the zoledronate and
control group were virtually covered by fibrous tissue.
The surface fraction for fibrous tissue was 97% (95% CI:
94%- 100%) in the zoledronate group compared to 97%
(95% CI: 94% - 99%) in the control group (p = 0.65). We
found no significant differences in the surface-fractions
of woven, lamellar, and total bone (p = 0.76, p = 0.42,
p = 0.71).
Discussion
The purpose of this study was to investigate whether
topical treatment with zoledronate could prevent bone
resorption and fibrous tissue formation in our large
animal model of micromotion induced bone resorption.
We found that zoledronate did not prevent formation of
a fibrous membrane, but was able to reduce bone re-
sorption and thickness of the fibrous membrane.
The used model is intended to imitate the bone to
cement interface of a total hip replacement. We have
previously demonstrated that our experimental model
are able to induce peri-implant bone resorption and
therefore also suitable to test local adjuvant therapies
against bone resorption [9]. The paired design allowed
us to eliminate the biological difference between
individuals.
Our study is limited by an observation period of
12 weeks and only nine animals completed the study.
Fig. 3 Representative photomicrographs of samples from the same animal. The samples were stained with basic fuchsin and counterstained with 2% light
green. Note the thick fibrous membrane around the control implant compared to the zoledronate implant. Solid bar = 1 mm. Dotted bar = 0.3 mm
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Non-significant differences should therefore be inter-
preted with caution.
Zoledronate is a potent inhibitor of bone resorption
[28]. We have previously shown that local treatment
with zoledronate can inhibit resorption of allograft and
increase fixation of both primary and revision implants
[29, 30]. In this study, we show that local treatment with
zoledronate can reduce resorption of bone in a 1 mm
peri-implant zone around an implant subjected to
controlled micromotion.
Our model of micromotion has a piston that allows a
0.5 mm movement of the implant during each loading.
The model was designed to imitate a cemented femoral
implant subjected to micromotion. The amplitude of
movement of our implant is above the accepted thresh-
old of 0.15 mm studies and suggested by Van der Voort
based on RSA and thereby comparable to clinical
implants with a high risk of as aseptic loosening [31].
Furthermore, the loading conditions of both clinical
femoral implants and our experimental implants are
comparable; both implants transfers load by shear forces
though the bone-cement imterface. In our model, move-
ment will occur at the implant-to-bone interface during
each gait cycle and thereby create high shear forces and
strain between the implant and tissue in contact with
the implant. According to studies by and Carter and
Giori, the amplitude of strain dictates which tissue can
be formed [32, 33]. A high strain will induce bone re-
sorption and formation of fibrous tissue. We found that
local zoledronate treatment were able to partly counter-
act the strain/micromotion induced bone resorption and
preserve 14% more total bone compared to our control.
An interesting histological finding is the difference in
thickness of the fibrous membrane between the zoledro-
nate and control groups. We know from previous stud-
ies from our group that micromotion is able to induce
formation of a fibrous membrane [9, 34]. In this study
we observed that local zoledronate treatment histologi-
cally reduced the thickness of the membrane. It could be
that shear forces and stain at the tissue-to-implant inter-
face are to high to by counteracted by zoledronate.
Further away form the implant surface, strain and shear
forces diminishes and zoledronate are able to partly
preserve bone. We know from previous studies that in-
creased amount of bone and decreased amount of fi-
brous tissue in correlated to increased implant stability
[22]. The difference in fibrous layer thickness should
therefore have the potential to make the zoledronate
implants more mechanically stable.
It has previously been shown that systemic alendro-
nate is able to inhibit bone resorption in a canine osteo-
lytic hip arthroplasty model [15]. An animal study using
a rodent model has shown that systemic treatment with
alendronate or clodronate can reduce instability-induced
bone resorption, but high doses are needed [19]. One
likely explanation for the preserved bone volume density
found in this study is the inhibitory effect of zoledronate
on bone resorption. Previous studies have shown that
preservation of lamellar bone often leads to increased
formation of new bone [35–37]. The increased new bone
formation is explained by increased osteoconductive
properties of the preserved lamellar bone. In this study,
we are not able to show a statistically significant increase
in peri-implant formation of new bone (8% in
Fig. 4 Tissue-volume fractions in a 0–1 mm zone around implants. Paired data connected by line
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zoledronate group vs. 3% in control group, p = 0.08).
One possible explanation could be a to short observation
period for new bone formation to occur. The effect on
bone formation and resorption has been shown to be
different over time [37]. A longer observation period
might have shown a more pronounced effect of zoledro-
nate on both bone formation and resorption.
Local treatment with zoledronate was not able to pre-
vent formation of peri-implant fibrous tissue. However,
zoledronate was able to reduce the thickness of the peri-
implant fibrous membrane. This is in agreement with
results from another study where local alendronate
treatment reduced formation of soft tissue, but did not
prevent its formation [19]. It is also in agreement with a
clinical study were local ibandronate treatment reduced
occurrences of radiolucent lines around acetabular cups
lines, but not prevented them [16]. Based on our previ-
ous study were systemic alendronate reduced bone re-
sorption around an unstable implant, we expected that a
stronger anti-resorptive stimulus could be obtained with
local zoledronate. We therefore expected that local zole-
dronate could prevent bone resorption and formation of
fibrous tissue. It may be that implant micromotion is a
too strong stimulus for even local zoledronate being able
to completely prevent bone resorption. Another explan-
ation could be that the single dose of zoledronate acts
only as a defense again bone-resorption for a limited
amount of time. Zoledronate, released from bone by
osteoclastic resorption, could be slowly washed away
from the implant-bone interface. By time the concentra-
tion will be too low to inhibit the continuous strong
bone resorptive stimulus from micromotion.
In clinical practice, soaking the bone bed before
implantation is a simple procedure. We know from a
previous studies that the effect on implant osseointegra-
tion of local bisphosphonate is dose-dependent [29, 38].
Bisphosphonate bound to bone will only exert its effect
on the osteoclast during bone resorption and intra-
cellular internalization [39]. However, any cell, including
bone-forming cells, can internalize unbound bisphos-
phonate. Removal of unbound bisphosphonate by irrigat-
ing the bone bed after soaking it with bisphosphonate is
therefore of importance.
Conclusion
In conclusion, this study indicates that local treatment
with zoledronate can reduce micromotion induced bone
resorption, but not prevent it. Studies investigating the
effect of different zoledronate doses and observation
periods are needed.
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